A randomized comparison of side effects and patient convenience between Cyclogest® suppositories and Endometrin® tablets used for luteal phase support in IVF treatment

Objective: This study compared side effects and patient convenience of vaginal progesterone suppositories (Cyclogest (R)) progesterone tablets (Endometrin (R)) used for luteal phase support in in vitro fertilization/embryo transfer (IVF/ET) cycles using pituitary downregulation. Study design: One hundred and thirty-two infer-tile patients were randomized on the day of ET by a computer-generated randomization list in sealed envelopes to receive either Cyclogest (R) 400 mg or Endometrin (R) 100 mg twice daily for 14 days. On days 6 and 16 after ET, they rated side effects and patient convenience into four grades: none, mild, moderate and severe by completing a questionnaire. Results: No significant differences in perineal irritation were found on days 6 and 16 after ET between the two groups, although there was a trend of fewer patients with perineal irritation in the Endometrin (R) group. Significantly more patients in the Endometrin (R) group had difficulty of administration on day 6 after ET. There were no differences in the hormonal profile on day 6 after ET and IVF outcomes between the two groups. Conclusion: There was no difference in perineal irritation after the use of Cyclogest (R) suppositories or Endometrin (R) tablets for luteal phase support although more patients found administration of Endometrin (R) tablets difficult. (c) 2006 Elsevier Ireland Ltd. All rights reserved.